Myocarditis Treatment Market Size, Share, and Analysis, By Drug Class (Inotropic Agents, Beta-adrenergic Blockers, Diuretics, and Others), By Route of Administration (Oral and Injectable), By Disease Type (Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast 2025-2032

Myocarditis is the inflammation of the heart muscle that is caused due to viral infections or other inflammatory conditions such as autoimmune diseases. This inflammation can weaken the heart, affecting its ability to pump blood efficiently. Acute myocarditis causes permanent damage to the heart muscle, which leads to myocardial infarction, heart failure, stroke, and arrhythmias. Early diagnosis of the disease is important to prevent long-term heart damage; therefore, proper treatment options that aim to reduce congestion during heart failure are considered.

Furthermore, growing awareness regarding the early diagnosis of myocarditis, increasing drug pipelines, and advancements in therapeutic methods are some of the factors driving the growth of the myocarditis treatment market.

• For instance, according to data published by Pharmaceutical Technology, in December 2023, 10 myocarditis drugs in the pipeline are being developed by companies such as Swedish Orphan Biovitrum, Bristol-Myers Squibb, and Cantargia and one drug is developed by the academic institute.

Moreover, the rising incidence of myocarditis globally, coupled with the aging population, is contributing to market growth. For instance, according to data published by the National Center for Biotechnology Information (NCBI), in November 2023, annually 1.5 million cases of myocarditis were reported globally.

Impact of COVID-19 on the Myocarditis Treatment Market

The global myocarditis treatment market experienced a decline in its growth during the COVID-19 outbreak due to lockdown restrictions. The decline in market growth was due to a lower number of people visiting clinics and hospitals for emergency treatment to contain the spread of coronavirus. According to an article published by the National Center for Biotechnology Information (NCBI), in 2020, the Food and Drug Administration (FDA) issued guidelines to conduct clinical trials focusing only on the development of COVID-19 vaccines, which halted the ongoing/upcoming clinical trials of other diseases. These factors restricted the market growth.

However, the market is projected to expand during the forecast period owing to increased cases of myocarditis among the adult population after taking the second dose of COVID-19 vaccination. The growing number of cases has led to an increasing demand for new therapeutic medicines, which has contributed to the growth of the market.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Myocarditis - By Key Countries/Regions, 2022/2023
• Pipelines Analysis, Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• Impact of COVID-19 on the Market

Analysis by Route of Administration

On the basis of the route of administration, the oral segment accounted for a significant market share in 2023. The growth of the segment is attributed to its cost-effectiveness, high patient compliance, and non-invasiveness. According to an article published by the National Center for Biotechnology Information (NCBI) in 2021, approximately 60% of established small-molecule drug products are administered through the oral route.

Furthermore, the injectable segment is expected to grow at a considerable CAGR during the forecast period owing to faster absorption and improved bioavailability of drugs. Injectable routes are suitable for several drugs, mostly in situations where a person needs a consistent, high, and urgent dose. This is one of the key factors contributing to the segment growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America is projected to account for a significant share of the global myocarditis treatment market in 2023. The regional growth is attributed to the rising number of clinical trials by key market players to launch new products in the region.

• For instance, in May 2022, Cardiol Therapeutics received U.S. FDA authorization to perform a multi-center Phase II study of CardiolRx for acute myocarditis and recurrent pericarditis.

Furthermore, the Asia Pacific market is expected to grow at a significant CAGR during the forecast period. The regional growth is attributed to the rising burden of cardiovascular diseases coupled with growing awareness among the population regarding early diagnosis of myocarditis.

Key Players Covered

The report includes the profiles of key players such as Cardiol Therapeutics, CEL SCI, Evotec SE, Swedish Orphan Biovitrum AB, Novartis AG, Bristol-Myers Squibb Company, and others.

Key Industry Developments

• In September 2023, Cardiol Therapeutics Inc., entered a collaboration agreement with clinical research centers, which aims to start enrolling in ARCHER, a Phase II Trial of CardiolRx, for acute myocarditis treatment.
• In June 2023, Bristol Myers Squibb received European Commission (EC) authorization for its drug, CAMZYOS. The drug is to be used for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
• In February 2021, Novartis received U.S. FDA authorization for the broader use of its drug Entresto. The drug can be used to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure.